Japan Chemical Daily

Japan's leading chemical industry newspaper

Log In

Kyoto University Venture Thyas Uses iPS Cells to Generate Killer T Cells for Cancer Treatment

Filed Under: Innovation Tagged With: , , , ,

Thyas Co. Ltd., a venture from Kyoto University, is developing cancer immunotherapy technologies based on creating induced pluripotent stem (iPS)…...

Please subscribe to read the full story.

Subscribe Free Trial

Related Articles:

Tokyo Tech Devises a New Generation of BPA for Use in Chemical Surgery
Tokyo Tech Devises a New Generation of BPA for Use in…
Tosoh Enables Simple Removal of Regenerative Medicine Cells Using New Thermoresponsive Polymer
Tosoh Enables Simple Removal of Regenerative Medicine Cells…
Menard, Mandom Expand Cosmetics Research to Look at Stem Cells
Menard, Mandom Expand Cosmetics Research to Look at Stem…
Tokyo Institute of Technology, Kanto Chemical Develop Growth Medium for iPS Cell-Derived Small Intestine Models
Tokyo Institute of Technology, Kanto Chemical Develop Growth…
LSII to Launch Clinical Trials of Muse Cells to Treat Respiratory Failure in COVID-19 Patients
LSII to Launch Clinical Trials of Muse Cells to Treat…
Panasonic Aims to Reduce Cost of Pure Hydrogen Fuel Cells
Panasonic Aims to Reduce Cost of Pure Hydrogen Fuel Cells